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Abstract
Dietary recommendations suggest decreased consumption of SFA to minimise CVD risk; however, not all foods rich in SFA are equivalent. To evaluate the
effects of SFA in a dairy food matrix, as Cheddar cheese, v. SFA from a vegan-alternative test meal on postprandial inflammatory markers, a randomised
controlled cross-over trial was conducted in twenty overweight or obese adults with metabolic abnormalities. Individuals consumed two isoenergetic high-
fat mixed meals separated by a 1- to 2-week washout period. Serum was collected at baseline, and at 1, 3 and 6 h postprandially and analysed for inflam-
matory markers (IL-6, IL-8, IL-10, IL-17, IL-18, TNFα, monocyte chemotactic protein-1 (MCP-1)), acute-phase proteins C-reactive protein (CRP) and
serum amyloid-A (SAA), cellular adhesion molecules and blood lipids, glucose and insulin. Following both high-fat test meals, postprandial TAG concen-
trations rose steadily (P < 0·05) without a decrease by 6 h. The incremental AUC (iAUC) for CRP was significantly lower (P< 0·05) in response to the
cheese compared with the vegan-alternative test meal. A treatment effect was not observed for any other inflammatory markers; however, for both
test meals, multiple markers significantly changed from baseline over the 6 h postprandial period (IL-6, IL-8, IL-18, TNFα, MCP-1, SAA). Saturated
fat in the form of a cheese matrix reduced the iAUC for CRP compared with a vegan-alternative test meal during the postprandial 6 h period. The
study is registered at clinicaltrials.gov under NCT01803633.
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One independent risk factor for CVD is postprandial inflam-
mation, or inflammation in the hours immediately following a
meal (for a review, see Burdge & Calder(1)). Consumption of a
meal promotes a transient inflammatory response, the intensity
and duration of which is determined by the composition of the
meal (for a review, see Margioris(2)). A high-fat meal increases
TAG- rich lipoproteins, a phenomenon known as postprandial
lipaemia, which is linked to CVD risk(3). Both postprandial
inflammatory and lipaemic responses contribute to a chronic
pro-inflammatory state observed in metabolically abnormal
individuals, termed metabolic inflammation, which further
exacerbates CVD risk (for a review, see Margioris(2)).
Abbreviations: CH, cheese; CRP, C-reactive protein; HOMA-IR, homoeostasis model assessment of insulin resistance; iAUC, incremental AUC; MCP-1, monocyte chemo-
tactic protein-1; SAA, serum amyloid-A; sICAM, soluble intracellular adhesion molecule; VA, vegan alternative; WC, waist circumference.
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Observational studies have linked saturated fat consumption
with increased risk for CVD development(4,5). The specific
effects of varying fatty acid composition have been investi-
gated extensively, with the latest consensus purporting that
MUFA and PUFA are beneficial whereas SFA and trans-fats
are deleterious in terms of plasma lipid profiles and CVD
risk (for a review, see Erkkilä et al.(6)). Decreasing SFA intake
has been the cornerstone of dietary recommendation for sev-
eral decades, including the current Dietary Guidelines for
Americans 2010(7). However, decreasing SFA intake may not
lower CVD risk in a subset of the population(8). In fact, a
recent meta-analysis of twenty-two prospective studies found
that consumption of certain dairy foods that are high in
SFA, specifically cheese, was found to be inversely associated
with CVD risk(9). The postprandial effect of dairy foods is
more than the sum of its parts. When analysed individually,
dairy-derived proteins(10), SCFA(11), bacteria in fermented
dairy products (for a review, see Settanni & Moschetti(12)),
and milk fat globule membrane(13), have shown favourable
or neutral effects on CVD risk. However, little is known
about the combination of components in cheese and their
interactions, known as the food matrix (for a review, see
Jacobs et al.(14)), on postprandial lipaemia and inflammation.
The majority of studies examining postprandial inflammation
in response to high-fat dietary challenges compared SFA
with MUFA and PUFA, but not with other high-SFA foods
that varied in fatty acid composition(15,16). Additionally, the
consumption of SFA from dairy products in the context of
a complex matrix such as cheese rather than as just milk,
cream or butter have not been examined. This is surprising
considering that cheese is the primary source of SFA in the
American diet(17). A recent study documented that approxi-
mately 5 % of US adults are vegetarian, of whom about half
are vegan(18). These numbers have doubled from 2009 to
2011. The Dietary Guidelines Advisory Committee recently
noted that a diet higher in plant-based foods is more health
promoting than the current US diet(19). This is echoed in a
position paper from the Academy of Nutrition and Dietetics
reporting that appropriately planned plant-based diets may
help prevent and treat certain chronic diseases(20). While
there is research supporting a plant-based diet for optimal
health, this type of dietary pattern can still include plant-based
saturated fats, such as palm oil. Yet the postprandial effects of
high-fat meals containing SFA from plant sources (i.e. palm
oil) have not been examined in human subjects. In mice, con-
sumption of a diet enriched with palm oil induced the highest
levels of inflammation compared with other lipids tested,
including milk fat(21). Given the increasing interest in plant-
based diets by the public, this study set out to address the
gap in knowledge about the effects of dietary saturated fat
from plant sources v. from dairy sources on postprandial
inflammation. Specifically, the aim of this study was to deter-
mine the effects of consuming two mixed isoenergetic meals
high in SFA from cheese compared with a non-dairy cheese
alternative plus palm oil on postprandial inflammatory and
metabolic markers. We hypothesised that consumption of a
meal high in SFA from Cheddar cheese in overweight and
obese individuals with metabolic abnormalities would result
in lower circulating pro-inflammatory markers in the postpran-
dial state compared with a meal with equal amounts of SFA
from palm oil plus a non-dairy cheese substitute.
Methods
Participants
A total of twenty adults (seven men and thirteen women) were
recruited. Inclusion criteria were: age 18–65 years, and either a
BMI between 25 and 29·9 kg/m2 plus two traits of the meta-
bolic syndrome defined by the American Heart Association as
waist circumference (WC) > 40 inches (>102 cm) for men and
35 inches (>89 cm) for women, fasting plasma TAG ≥ 150
mg/dl (≥ 1.69 mmol/l), fasting plasma HDL-cholesterol
<40 mg/dl (<1.03 mmol/l) for men and <50 mg/dl (<1.29
mmol/l) for women, blood pressure ≥130/85 mmHg, and
fasting glucose ≥100 mg/dl (≥5.6 mmol/l)(22), or obese
(BMI between 30 and 39·9 kg/m2). Participants’ insulin sensi-
tivity was determined from their fasting plasma glucose and
insulin using the homoeostasis model assessment of insulin
resistance (HOMA-IR) with 2·6 or greater as a cut-off point
of insulin resistance(23). Participants’ inflammation status was
determined with the measurement of fasting circulating CRP
concentrations at 3 mg/l or above as associated with increased
CVD risk(24). Exclusion criteria included immune-related dis-
eases, gastrointestinal disorders, cancer, type 2 diabetes, use
of over-the-counter anti-obesity agents or corticoid steroid
within the last 12 weeks, daily use of anti-inflammatory pain
medication, self-reported eating disorder, poor vein assess-
ment determined by the phlebotomist, known allergy or
intolerance to study food, vegetarian, consume >1 serving of
fish per week, >14 g of fibre per 1000 kcal (4184 kJ)/d,
<16:1 of total dietary n-6:n-3 ratio, >1 % of daily energy as
trans-fats, initiation of fish, krill, flax, borage or primrose
seed oils within the last 12 weeks, dietary supplements of con-
centrated soya isoflavones, resveratrol, other polyphenols, ini-
tiation of statin therapy within the last 12 weeks, >10 % weight
loss or gain during the past 6 months, initiation of an exercise
programme in the last month, plan to become pregnant in the
next 6 months, pregnancy or lactation, recent initiation,
change, or cessation of hormonal birth control within the
last 12 weeks, and use of tobacco products. To establish ful-
fillment of the enrolment criteria subjects completed a ques-
tionnaire regarding their health history, diet and medication,
completed an online FFQ, provided a fasting blood sample
for analysis of blood lipids and glucose, and were assessed
for weight, height and WC at the screening visit.
The Institutional Review Board of the University of
California at Davis approved the study protocol, and all parti-
cipants gave written informed consent prior to starting the
study. The study is registered at clinicaltrials.gov under
NCT01803633.
Study design
A randomised, cross-over design was used in which investiga-
tors were blind to treatment order. All participants received
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both treatments. To avoid any interaction effects a 1- to 2-week
washout period was observed between treatments. Treatment
order was randomly assigned using a random allocation
sequence generator (randomization.com; seed# 4234) (Fig. 1).
Volunteers were instructed to avoid alcohol consumption,
non-steroidal inflammatory drug use, and any anti-inflammatory
supplements such as fish, krill, flax, borage or primrose seed oils
72 h prior to each test day. Volunteers were instructed to avoid
seafood, and were asked to record everything they consumed
24 h before the test day, not to exercise, and not to consume
anything past 20.00 hours. We analysed the 1-d dietary records
using the Nutrition Data System for Research (NDSR;
University of Minnesota) to ensure that participants complied
with pre-study dietary instructions.
After a 10–12 h fast participants arrived at the Western
Human Nutrition Research Center. Upon arrival volunteers
turned in their 1-d food record, filled out a modified gastro-
intestinal questionnaire(25), provided a urine sample and fasted
blood draw via venepuncture. Measurements for blood pres-
sure, heart rate, weight and WC were taken. Participants then
consumed the high-fat breakfast challenge within 20 min.
Postprandial blood draws and urine samples were collected at
1, 3 and 6 h. These time points were chosen based on previous
studies demonstrating peak cytokine concentrations observed 3
or 6 h after a high-fat meal challenge(16) and oxylipins and eico-
sanoids change at 1 and 6 h from baseline(26,27).
Throughout the test day participants were not allowed to
consume any food, but could drink bottled water ad libitum.
Participants either stayed at the research centre or left between
blood draws to attend classes or return to work. To minimise
physical activity, if participants left the research facility they did
so by car, not by foot or bicycle, and returned approximately
15 min and rested for 10 min prior to the next blood draw.
Dietary challenges
The dietary challenges consisted of grilled sandwiches servedwith
a blended beverage. The cheese (CH) test meal consisted of
medium Cheddar cheese (Tillamook Medium Cheddar Cheese)
while the vegan alternative (VA) consisted of Daiya Cheddar
cheese (Daiya). Both sandwiches were made with 100 % Whole
Wheat Sandwich Thins (Oroweat). Each meal was paired with
a blended beverage to allow for the matching of energy, total
fat, carbohydrates and protein (Supplementary Table S1).
Each of the two meal challenges provided 40 % of the par-
ticipant’s total energy intake. Energy intake was determined by
using the National Academy of Sciences equation from the
Institute of Medicine Dietary Reference Intake that takes phys-
ical activity into account in addition to sex, age, weight and
height(28). Physical activity was determined using the Baecke
Physical Activity questionnaire, which assesses habitual physic-
al activity and identifies three components of physical activity:
work, sport and leisure time excluding sport(29).
Each meal consisted of about 50 % fat, about 40 % carbo-
hydrates, and about 10 % protein and delivered between 45
and 75 g of fat depending on the individual’s energy intake.
Assessed for eligibility (n 76)
Excluded (n 56)
Not meeting inclusion criteria (n 54)
Declined to participate (n 2)
Randomised (n 20)
CH treatment (n 10) VA treatment (n 10)
Completed intervention (n 10)Completed intervention (n 10)
Male = 4
Female = 6
CH treatment (n 10)
Completed intervention (n 10)
Male = 3
Female = 7
Male = 3
Female = 7
VA treatment (n 10)
Completed intervention (n 10)
Male = 4
Female = 6
Washout (1–2 weeks)
Analysed (n 20)
Excluded form analysis (n 0)
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Fig. 1. Enrolment and follow up of participants in the randomised cross-over trial. CH, Cheddar cheese treatment; VA, vegan-alternative treatment.
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The Cheddar cheese provided 44 % of the fat in the CH meal
and palm oil provided 38 % of the fat in the non-dairy cheese
substitute meal. The meals were isoenergetic, had the same
macronutrient composition as well as similar MUFA, PUFA
and SFA composition (Table 1). The only difference between
the test meals was individual fatty acid composition, the matrix
in which it was delivered, dietary cholesterol and Ca concentra-
tions. Participants were instructed to eat everything on their
plate and rinse their blended beverage cup with water, then
drink the rinse water.
Blood analyses
Whole blood was collected at the Western Human Nutrition
Research Center by a trained phlebotomist for each time
point. Whole blood was centrifuged in a tabletop ultracentrifuge
for 10 min at 4°C at 1300 g within 30 min of collection. Plasma
was immediately separated into 1·5ml aliquots, and immediately
frozen at –70°C until analysis. Serum was isolated and trans-
ferred into 1·5 ml aliquots after clotting for 30 min on ice and
centrifugation and immediately frozen at –70°C until analysed.
Inflammatory markers
Serum collected at 0, 1, 3 and 6 h was used to analyse cytokines
(IL-10, IL-17, IL-1β, IL-2, IL-6, IL-8, monocyte chemotactic
protein-1 (MCP-1), TNFα), as well as the acute-phase proteins
(C-reactive protein (CRP), serum amyloid-A (SAA)), and vascu-
lar injury molecules soluble intracellular adhesion molecule
(sICAM) and soluble vascular adhesion molecule. Plasma was
used to measure IL-18 concentrations. Analysis of all inflamma-
tory markers was completed using an electro-
chemiluminescence detection system using multiarray technol-
ogy (SECTOR Imager 2400; Meso Scale Discovery) according
to the manufacturer’s instructions. In brief, this system uses
multi-array ninety-six-well plates with multi-electrodes per
well. Each electrode has a different capture antibody, allowing
for the analysis of multiple markers of interest at once. The
assay procedure is similar to that of a classic sandwich
ELISA. A small amount of sample (25–50 µl) serum or plasma
is added to each well. The markers of interest bind to the pre-
coated capture antibodies. To complete the ‘sandwich’ a detec-
tion antibody that is conjugated with a label is added and binds
to the analyte. Finally the addition of a read buffer allows for the
activation of the label on the detection antibody, resulting in illu-
mination after electrochemical stimulation via voltage that runs
through the plate in the reader. The instrument measures the
intensity of the light to quantify a measure of each analyte.
Metabolic parameters
Plasma glucose, insulin and a lipid panel including TAG, total
cholesterol, HDL-cholesterol, LDL-cholesterol, HDL:LDL
ratio and non-HDL-cholesterol were assessed by the clinical
laboratory at the University of California Medical Center
(Sacramento, CA) at baseline and at 1, 3 and 6 h after consum-
ing the high-fat challenge meal.
Clinical characteristics
Anthropometric data were collected at the screening visit and each
test day visit. Measurements included body weight (6002
Wheelchair Scale; Scale-tronix), WC (QM2000 Measure Mate;
QuickMedical), height (Ayrton Stadiometer Model S100; Ayrton
Corporation), blood pressure and resting heart rate (Carescape
V100 with Critikon Dura-cuf for either adults or large adults;
GE Medical Instruments). BMI was calculated as kg/m2.
Statistical analysis
This study was a 2 × 4 factorial design: two treatments x four
time points. Sample size was calculated based on our primary
outcome marker using the means and standard deviations for
IL-6 from a similar human study with overweight volun-
teers(16). A secondary analysis was also conducted on other
Table 1. Nutrient composition of the test meals†
(Mean values and standard deviations)
CH meal VA meal
Mean SD Mean SD
Energy (kcal) 1002·9 114·5 1002·1 113·9
Energy (kJ) 4196·0 478·8 4192·6 476·3
Total carbohydrate
g 103·7 11·8 105·0 11·9
% total energy 39·3 0·0 39·0 0·0
Total protein
g 27·8 3·2 28·8 3·3
% total energy 11·0 0·0 10·2 0·0
Total fat
g 56·6 6·5 57·9 6·6
% total energy 49·6 0·0 50·8 0·0
Total SFA
g 19·2 2·2 19·7 2·2
% total energy 16·8 0·0 17·2 0·0
Total MUFA
g 21·1 2·4 21·7 2·5
% total energy 18·6 0·0 19·1 0·0
Total PUFA
g 13·4 1·5 13·8 1·6
% total energy 11·8 0·0 12·1 0·0
SFA 4 : 0 (butyric acid) (%)*** 1·4 0·0 0·0 0·0
SFA 6 : 0 (caproic acid) (%)*** 0·7 0·0 0·1 0·0
SFA 8 : 0 (caprylic acid) (%)*** 0·4 0·0 0·9 0·0
SFA 10 : 0 (capric acid) (%) 0·8 0·0 0·8 0·0
SFA 12 : 0 (lauric acid) (%)*** 0·7 0·0 5·6 0·0
SFA 14 : 0 (myristic acid) (%)*** 4·5 0·0 2·5 0·0
SFA 16 : 0 (palmitic acid) (%)*** 16·10 0·01 20·24 0·02
SFA 18 : 0 (stearic acid) (%)*** 7·71 0·00 3·28 0·00
SFA 20 : 0 (arachidic acid) (%)*** 0·00 0·00 0·12 0·00
SFA 22 : 0 (behenic acid) (%)*** 0·22 0·00 0·15 0·00
MUFA 16 : 1 (palmitoleic acid) (%)*** 1·50 0·00 0·39 0·00
MUFA 18 : 1 (oleic acid) (%)* 34·97 0·02 36·78 0·01
MUFA 20 : 1 (gadoleic acid) (%)*** 0·22 0·00 0·37 0·00
PUFA 18 : 2 (linoleic acid) (%) 22·98 0·02 21·80 0·02
PUFA 18 : 3 (linolenic acid) (%)*** 0·72 0·00 1·94 0·00
Cholesterol (mg)*** 79·20 9·01 0·00 0·00
Total dietary fibre (g)*** 12·27 1·39 15·60 1·77
Ca (mg)*** 487·11 55·38 129·71 14·75
CH, cheese; VA, vegan alternative.
Significant difference between the two meals: *P < 0·05, **P < 0·005, ***P < 0·0005.
†Comparison of the two dietary challenges. Nutrient composition was obtained
using Nutrition Data System for Research (NDSR). Test meals were based on
total energy expenditure thus values shown are average of all test meals (n 20).
4
journals.cambridge.org/jns
pro-inflammatory cytokines, acute-phase proteins and vascular
adhesion molecules based on previous research that showed
changes in these markers in healthy participants in response
to high-fat test meals containing similar amounts of fat as
used in our study (for a review, see Herieka & Erridge(30)).
To ensure that our sample size reflected the number of subjects
needed to be 95 % confident of our results, with 80 % power we
needed eighteen volunteers. To account for attrition 10 % was
added for a final sample size of twenty. All data were checked
for normality visually with histograms and Q-Q plots as well as
numerically with the Shapiro–Wilk test. Data were transformed
as needed prior to conducting statistical analysis. For cytokines
with <10 % of samples below the detection limit (IL-17 only)
the value recorded was the lowest limit of detection provided
by the manufacturer and divided by 10. For dependent variables
with >10 % of the data below the detection limit these markers
were excluded from statistical analysis (IL-1β and IL-2).
Dietary data between treatments were compared using a
paired two-tailed t test. Differences in baseline concentration
between treatments were tested using a paired sample two-
tailed t test. A mixed linear model was conducted with treat-
ment and time as fixed factors, subjects as the random effect
and treatment × time as the interaction term. If time was signifi-
cant, multiple comparison post hoc analysis with Bonferroni cor-
rection was carried out to compare the concentrations at 0 v.
1 h, 0 v. 3 h, 0 v. 6 h, 1 v. 3 h, 1 v. 6 h, and 3 v. 6 h.
The incremental AUC (iAUC, area above baseline) and decre-
mental AUC (area below baseline) using the conventional trapez-
oid method were used to compare postprandial responses
between groups (response to test meals)(31). The iAUC was cho-
sen over the total AUC because it reflects the postprandial rise of
metabolite concentrations above the non-zero fasting value(32).
iAUC between CH and VA groups were compared via paired
t tests and ANCOVA with subject as the random variable, treat-
ment as the fixed factor and baseline CRP concentrations as the
covariate.
We conducted secondary analyses to determine if pre-
existing clinical conditions affected the inflammatory response
to the high-fat meal challenge. We coded subjects for high v.
low baseline CRP levels known to be associated with increased
vascular risk (<3 mg/l, n 10; or >3 mg/l, n 10). ANCOVA
was used to identify statistically significant differences in post-
prandial inflammatory markers between treatments using base-
line values of CRP as the covariate.
Differences were considered significant at P < 0·05.
Statistical analyses were performed using SPSS version 20.0
software for Macintosh (SPSS).
Results
Subject characteristics
A total of seventy-six participants underwent screening. As
shown in Fig. 1, twenty subjects were randomly assigned to
one of two treatment groups in a cross-over design: CH
(n 20) and VA (n 20). After a 1- to 2-week washout period
each subject crossed over to the remaining treatment. All sub-
jects completed both treatment arms with no attrition.
The baseline characteristics of the subjects are shown in
Table 2 and metabolic characteristics of each participant are
found in Supplementary Table S2. Our study population was
predominantly female (65 %) and Caucasian (75 %). With
respect to the metabolic syndrome, six of the twenty partici-
pants had the metabolic syndrome with three or more of the
five diagnostic traits, seven participants had two of the five
traits, and seven participants had only one trait. When asses-
sing their metabolic and inflammatory status, fourteen of the
twenty participants were considered insulin resistant with a
HOMA-IR >2·6; ten of the twenty participants had a high
baseline CRP concentration (>3 mg/l); and six of the twenty
participants had both a HOMA-IR >2·6 and baseline CRP
concentration above 3 mg/l. Additionally, thirteen of the
twenty participants had a BMI of 30 kg/m2 or greater and
were abdominally obese (WC >35 inches (>89 cm) for
women and >40 inches (>102 cm) for men).
Dietary intake
Dietary analysis of the 1-d food record completed prior to
each test day revealed no significant differences in consump-
tion of macro- and micronutrients (data not shown).
Metabolic parameters
Baseline and postprandial changes for metabolic markers (total
cholesterol, HDL, LDL, TAG) are shown in Table 3. No
time × treatment interaction or main effect of treatment were
observed for any of these markers; however, there was a sig-
nificant difference over time for all markers.
Postprandial glycaemia
At baseline, insulin concentrations did not differ between test
days (P = 0·8) while glucose concentrations did (P = 0·004);
however, since there was no treatment effect this statistical dif-
ference was considered a random occurrence. Following each
meal, there was a rapid increase in both glucose and insulin
from 0 to 1 h (P = 0·029 and P < 0·0005, respectively) fol-
lowed by a decrease from 1 to 3 h (P< 0·0005 for both)
and an increase in glucose from 3 to 6 h (P= 0·01). The glu-
cose (P = 0·602) and insulin (P= 0·908) responses did not dif-
fer between the treatments (Fig. 2).
Postprandial lipaemia
Fasting/baseline TAG concentrations were comparable
between the two treatments (P = 0·245). After meal consump-
tion, postprandial TAG concentration rose steadily (P < 0·05
for all time points: 0–1, 0–3, 0–6, 1–3, 1–6, and 3–6 h) with
no sign of a decrease at the 6 h time point (Fig. 3).
Inflammatory markers
IL-1β and IL-2 were below the detection limit (for about 70
and 35 % of samples, respectively) and therefore, excluded
from the statistical analysis. Similar results for these two
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particular cytokines have been observed(33). Baseline concen-
trations of all markers related to inflammation were compar-
able between the two interventions. CRP as the iAUC was
the only marker with a significant difference between
treatments, with the VA meal resulting in a significantly greater
overall CRP concentration (P = 0·033) when compared with
the CH meal (Fig. 4). There was no treatment effect observed
for any of the other inflammatory markers. However, multiple
Table 2. Subject baseline characteristics*
(Mean values and standard deviations)
Mean SD MetS criteria† Range
Age (years) 49 11 24–64
Participants with high CRP (years)‡ 50·6 12·3 24–64
Participants with low CRP (years)‡ 47·9 9·4 25–57
Weight (kg) 90·5 9·5 66·1–109·0
Height (m) 1·7 0·1 1·5–1·8
BMI (kg/m2) 31·7 2·9 24·4–37·1
WC (inches) 38·7 2·4 32–42·4
WC, males (inches)§ 39·4 1·3 >40 37·2–41
WC, females (inches)§ 38·3 2·8 >35 32–42·4
WC (cm) 98·3 6·1 81–107·7
WC, males (cm)§ 100·1 3·3 >102 94·5–104·1
WC, females (cm)§ 97·3 7·1 >89 81·3–107·7
Systolic BP (mmHg) 127 14·1 ≥130 98–151·5
Diastolic BP (mmHg) 78·1 9 ≥85 57–98·5
HDL-cholesterol
mg/dl 45·9 9·7 31–60
mmol/l 1·19 0·25 0·80–1·55
HDL-cholesterol, male§
mg/dl 41·9 10·3 <40 31–56
mmol/l 1·08 0·27 <1·03 0·80–1·45
HDL-cholesterol, female§
mg/dl 48·1 9·0 <50 33–60
mmol/l 1·24 0·23 <1·29 0·85–1·55
Fasting glucose
mg/dl 91·8 7·4 ≥100 78–104
mmol/l 5·1 0·4 ≥5·6 4·3–5·8
Fasting TAG
mg/dl 124·4 45·7 ≥150 65–224
mmol/l 1·40 0·52 ≥1·69 0·73–2·53
MetS, metabolic syndrome; CRP, C-reactive protein; WC, waist circumference; BP, blood pressure.
* Measurements taken at screening visit (n 20).
†MetS as defined by the American Heart Associations.
‡High baseline CRP n 10; low baseline CRP n 10.
§ Male n 7; female n 13.
Table 3. Concentrations of metabolic parameters before and after dietary challenge
(Pooled mean values and standard deviations)*
Time
0 h 1 h 3 h 6 h P
Mean SD Mean SD Mean SD Mean SD Treatment Time Interaction
Total cholesterol 0·87 0·001 0·96
mg/dl 209·0 44·3 215·1 45·2 209·9 42·4 212·2 45·6
mmol/l 5·41 1·15 5·57 1·17 5·44 1·10 5·50 1·18
HDL-cholesterol 0·95 0·002 0·51
mg/dl 47·3 10·9 48·3 11·4 45·8 10·0 45·7 10·5
mmol/l 1·23 0·28 1·25 0·30 1·19 0·26 1·18 0·27
LDL-cholesterol 0·98 <0·0005 0·24
mg/dl 135·8 38·5 132·4 38·8 126·2 36·4 124·6 41·1
mmol/l 3·52 1·00 3·43 1·00 3·27 0·94 3·23 1·06
HDL:LDL 4·6 1·1 4·6 1·0 4·7 1·1 4·7 1·1 0·93 <0·0005 0·38
TAG 0·60 <0·0005 0·67
mg/dl 129·0 44·4 171·2 54·7 199·9 75·2 218·6 77·4
mmol/l 1·46 0·50 1·93 0·62 2·26 0·85 2·47 0·87
Non-HDL-cholesterol 0·88 <0·0005 0·59
mg/dl 161·6 41·7 166·7 42·4 164·1 40·3 166·4 43·6
mmol/l 4·19 1·08 4·32 1·10 4·25 1·04 4·31 1·13
* Values are pooled means of both treatments since there was no treatment effect.
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markers did demonstrate an effect over time; SAA peaked at 1
h postprandially, IL-8 peaked at 3 h, while IL-6, IL-18, MCP-1
and TNFα peaked at 6 h postprandially (Table 4). Secondary
analyses based on baseline CRP values indicated that those
with pre-existing fasting CRP concentrations ≥3 mg/l did
not have a different response to treatment compared with par-
ticipants with baseline CRP concentrations <3 mg/l. We
conducted a secondary analysis using baseline CRP concentra-
tions as a stratification and found that volunteers who had a
baseline CRP value >3 mg/l had significantly higher concen-
trations of IL-6, SAA and sICAM at each time point compared
with the subjects who had baseline CRP values <3 mg/l.
Discussion
In this study, more than half (55 %) of the measured serum
inflammatory markers (IL-6, IL-8, IL-18, TNFα, MCP-1
and SAA) significantly changed over the 6 h postprandial per-
iod from baseline. Some of these findings are consistent and
some are not consistent with previous findings. Based on
the literature we had expected IL-6 to increase after the high-
fat challenges and peak around the 3 h time point, which has
previously been observed in men with the metabolic syn-
drome(34), overweight, obese men and women(16,35,36), and
healthy participants(37,38). However, to our surprise, the results
presented here showed an initial decrease in serum IL-6 con-
centration from baseline to the 1 h time point after consuming
both high-fat meals, followed by a significant rise at 3 h.
Manning et al.(36) reported similar findings of a temporary
decrease in IL-6 at 1 h after five test meals rich in cream,
olive oil, rapeseed oil, potato or All-Bran in obese and healthy
women, suggesting this might be due to the anti-inflammatory
effects of insulin(39). Our results support this, as insulin peaked
at 1 h, the time at which IL-6 concentrations were lowest.
IL-8 has not been commonly included in high-fat postpran-
dial inflammation studies(30); however, one postprandial study
found no change over time in overweight men(16) or in healthy
or obese women(36). IL-8 plays an important role in athero-
sclerosis in part by stimulating the production of other
pro-inflammatory cytokines such as TNFα and IL-1β(40).
Our results showed an initial rise in IL-8 concentrations
after both treatments with a peak at the 3 h time point. An
increase in IL-18 has been linked to CVD as it is a powerful
cytokine whose functions include the production of
pro-inflammatory cytokines such as TNFα, IL-1β, sICAM
and soluble vascular adhesion molecule(41). We are one of
the first groups to analyse the postprandial response of
IL-18 after a high-fat challenge. Our results showed a
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cal bars. * The VA meal resulted in a significantly greater overall CRP concen-
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significant increase in IL-18 after both high-fat treatments,
complemented by a similar increase in TNFα.
TNFα, a cytokine commonly measured in the postprandial
state, significantly increased after consumption of a large lipid
load and peaked at 6 h. These data are consistent with several
reports in healthy, type 2 diabetic, overweight, and obese men
and women after high-fat test meals(15,16,35,36,38). These data
may be explained by a greater number of monocytes in circu-
lation after a high-fat meal(42) and the rise in IL-8 and IL-18 at
3 h. While we do not have data on lymphocyte count for this
study, it would be of interest for future studies to incorporate
this analysis. Our results showed a significant increase in
MCP-1 from baseline at 1, 3 and 6 h after both meals.
Similar results have been reported previously in patients with
the metabolic syndrome who consumed a high-saturated fat
meal(43). However, not all studies have observed this postpran-
dial increase. Masson & Mensink(16) found a significant
decrease in serum MCP-1 in overweight men after both high-
fat meals that provided a total of 50 g of fat (butter v. linoleic
acid). In our study, the majority of the participants were
women and fat in the test meals was provided as 50 % of
each individual’s total energy expenditure and ranged from
45 to 75 g. It is not known if the total amount of fat consumed
or sex influence MCP-1 responses in the postprandial period.
SAA, an acute-phase protein that is primarily synthesised by
the liver, increases several-fold during the inflammatory
response to tissue injury(44). Its expression is stimulated by
cytokines (IL-6, IL-1β, TNFα)(45); however, SAA also stimu-
lates the secretion of IL-6 in connective tissue(46). SAA circu-
lates in the blood as part of HDL particles. In this complex,
SAA mediates the binding of HDL to proteoglycans, promot-
ing oxidation of the lipoprotein which impairs its ability to
remove cellular cholesterol, leading to cholesterol accumula-
tion in macrophages and foam cell formation(47). Based on
SAA’s ability to stimulate release of IL-6 by some tissues,
we expected to see a postprandial increase after the high-fat
meals. Instead, our results indicate a significant decrease
from baseline at the 6 h time point similar to the decline in
HDL-cholesterol over the postprandial period. A similar
decline in SAA concentration was observed by Esser et al.(48)
after providing healthy men a high-fat meal, while an increase
was seen after the same volunteers consumed a lower-fat
standard breakfast.
When the total concentration of each analyte over the 6 h
postprandial time was calculated as the iAUC, only CRP was
different between the two test meals, with the VA meal result-
ing in a significantly greater overall CRP concentration (P =
0·033) when compared with the CH meal. It is unknown
what components in cheese could reduce CRP concentration
or what components in the vegan test meal could stimulate
the increase in CRP concentration over the 6 h postprandial
time period. Schmid et al.(49) recently reported no difference
in postprandial CRP after consumption of a high-fat control
or high-fat control with milk in normal-weight, overweight
and obese men. CRP is an acute-phase protein that is synthe-
sised by the liver and increases several-fold during the inflam-
matory response to tissue injury(44) and responds to diet and
exercise(50,51). Its release by the liver is stimulated by IL-6Ta
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and alternatively, CRP also induces secretion of IL-6 by endo-
thelial cells(52). There are inconsistent findings on the effects of
a high-fat test meal on circulating CRP concentrations as a
result of the composition of the test meals used, target popu-
lations and timings of blood draws. For example, in lean indi-
viduals, plasma CRP measured 24 h after consumption of a
high-fat breakfast was significantly lower from baseline when
the breakfast contained a high v. low saturated:unsaturated
fat ratio(15). Other reports have shown that CRP does not
change within 6 h after consumption of high-fat mixed
meals in lean, overweight and abdominally obese partici-
pants(15,31,35,49). However, in type 2 diabetic participants,
CRP significantly increased from baseline within 4 h in
response to a high-fat test meal(53,54). In our study, the post-
prandial CRP response to the test meal could be explained
by the interaction between metabolic phenotype and the test
meal(31). Perez-Martinez et al.(31) recently reported higher post-
prandial plasma CRP to a high-fat meal in metabolically abnor-
mal subjects compared with normal, overweight and obese,
metabolically healthy patients. In our study, the majority of
our participants were metabolically abnormal according to ele-
vated circulating CRP (>3 mg/l), insulin resistance
(HOMA-IR > 2·6) and abdominal adiposity, yet we did not
have enough statistical power to determine the relationship
between the test meal and metabolic phenotype.
In our study, participants had slightly elevated insulin con-
centrations at baseline as well as high total and
LDL-cholesterol levels, which were expected based on the
inclusion criteria. As expected, both high-fat challenges signifi-
cantly increased plasma TAG concentrations postprandially;
however, the concentrations surprisingly peaked at 6 h. In
metabolically healthy individuals, the peak in plasma TAG
after a high-fat mixed meal occurs at about 4 h and declines
by 6 h(49,55). Because 70 % of our study participants were insu-
lin resistant, it is possible that the plateau in plasma TAG at 6
h is a result of their insulin resistance. These data are sup-
ported by the report that the postprandial plasma TAG con-
centration was found to plateau or peak at 6 h in individuals
with pre-diabetes and type 2 diabetes, after consumption of
a mixed meal containing 62 g fat(55).
Postprandial lipaemia has been shown to be strongly asso-
ciated with increased risk for coronary artery disease(3); how-
ever, while results from our study suggest that the
consumption of a meal enriched in SFA whether from
Cheddar cheese or plant fat was sufficient to cause postpran-
dial lipaemia, the postprandial cytokine response in this subject
pool was within the normal range. Other studies have found
that similar amounts of fat fed in mixed meals did induce a
lipaemic response and elicited postprandial inflammation(16,36).
In our study, the amount of fat used was high, with a mean of
59 g and ranged 45–75 g scaled to each individual’s energy
intake. Thus, we expected that inflammatory responses
would increase from baseline. It is possible that participants
in this study had delayed changes in postprandial inflammatory
markers given that their TAG levels were still increasing and
possibly had not peaked yet by 6 h.
Cross-sectionally, dairy product consumption has been
shown to be inversely correlated with inflammatory markers
among healthy adults(56). There are many possibilities to
explain how the myriad components in dairy products, their
interactions and synergy upon digestion and metabolism
could influence postprandial inflammation. Dairy components
that are reported to confer anti-inflammatory effects include
dairy proteins and peptides(57); SCFA(11) as trophic factors
for intestinal cells(58); starter and non-starter bacteria in fer-
mented dairy products(12); oligosaccharides as prebiotics(59);
and milk fat globule membrane and its proteins and polar
lipids(13). The effect of a meal composed of the dairy matrix
as Cheddar cheese on postprandial inflammation compared
with a non-dairy cheese substitute enriched with SFA in the
form of palm oil has not been investigated. Palm oil was cho-
sen as the source of SFA for the non-dairy cheese alternative
arm because it is commercially available, widely consumed
around the world and provides a similar SFA composition
to dairy fat compared with other plant-based fats.
The lack in finding a ‘treatment’ effect to the high-fat test
meals for several of the inflammatory markers could be
explained by several limitations. First, this study was powered
for postprandial changes in serum IL-6. Our sample size was
not large enough to permit statistical comparisons among dif-
ferent metabolic phenotypic groups (i.e. high v. low CRP; insu-
lin resistant v. sensitive, with or without the metabolic
syndrome). In our study, seven participants were diagnosed
with the metabolic syndrome and of the thirteen individuals
without classical metabolic syndrome, most had some meta-
bolic abnormalities: five had elevated plasma CRP, nine were
insulin resistant, and ten had abdominal adiposity.
Abdominal obesity is associated with a pro-inflammatory
state and shares features with the metabolic syndrome (for a
review, see Després & Lemieux(60)), and 70 % of the partici-
pants had abdominal adiposity, yet, we did not quantitatively
differentiate between visceral v. subcutaneous obesity.
Additionally, the lack of significance may also result from
the timing of blood collections against the normal diurnal
rhythm of inflammatory markers throughout the day(61). We
did not design the collection of time points to match the diur-
nal patterns of serum inflammatory markers since these pat-
terns vary for each inflammatory marker. Yet, we did ensure
that each time point was matched between the two test
meals to control for the time of day. While we observed a
time effect for some of the inflammatory markers it is import-
ant to note that all of these changes fell within the normal
range for each marker; thus the observed changes are probably
fluctuations around baseline(34). Furthermore, one possible
explanation for the lack of a treatment effect in all inflamma-
tory markers measured is that the serum TAG had not yet
peaked. Another limitation of the study is that the test meals
were not balanced for dietary Ca in each treatment. The
increased dietary Ca found in the CH meal could have formed
Ca soaps and thus lowered the amount of fatty acids that were
absorbed. However, while some studies found an effect of Ca
from cheese on faecal fat excretion(62), others did not(63).
Moreover, it would have been of interest to increase the sam-
ple size to allow equal numbers of men and women in the
study population as little is known about the sex difference
in inflammation. One study testing the inflammatory effect
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of a high-fat meal in overweight men and women found IL-6
to be significantly more elevated in women than men(64).
Finally, it is not well known if postprandial inflammation is
influenced by the hormonal changes associated with the men-
strual cycle as has been shown with fasting circulating lipids(65).
However, one study found that the variation contributed by
the postprandial period on circulating TAG and inflammatory
mediators was greater than the hormonal differences between
the follicular and luteal phases(66).
Conclusions
Results from this study provide important information about
the specific effects of the dairy-derived matrix v. non-dairy
alternative SFA as part of a mixed meal on a wide array of
inflammatory markers in the postprandial state, directly
addressing several key concerns and gaps in knowledge
addressed by a recent expert panel. There was no evidence
from this study in overweight and obese adults that there is
a difference in inflammatory response after a high-fat mixed
meal where the predominant fat source is cheese v. palm oil.
From the inflammatory markers that were measured only
IL-6, IL-8, IL-18, MCP-1, TNFα and SAA showed a post-
prandial response with respect to early postprandial cytokine
induction, regardless of which treatment was consumed.
When analysed as the iAUC, postprandial CRP was significant-
ly lower in response to the cheese compared with the vegan
test meal. Based on these results we conclude that while diet-
ary recommendations encourage a decreased consumption of
saturated fat to minimise CVD risk, saturated fat in the
form of cheese lowers postprandial inflammation compared
with plant sources of saturated fat.
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